Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

7 clinical studies listed.

Filters:

Necrotizing Enterocolitis (NEC)

Tundra lists 7 Necrotizing Enterocolitis (NEC) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT07944638

Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants

Babies born extremely preterm (before 28 weeks of pregnancy) miss most of the transfer of two long-chain fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), that normally passes from mother to baby in the last three months of pregnancy. Low levels of these fatty acids after birth have been linked to retinopathy of prematurity (ROP), an eye disease that can threaten vision, and to other complications of prematurity. In a Swedish randomized trial (Mega Donna Mega), an enteral supplement of ARA and DHA reduced severe ROP by about half. A similar supplement, NeoMega36, is now used in routine care in several European neonatal units and is being introduced in Sweden. This observational study examines whether the introduction of NeoMega36 into routine care is followed by less ROP and fewer other complications of prematurity. It compares infants born at 22+0 to 27+6 weeks of gestation who were cared for before NeoMega36 was introduced at their unit (historical period) with infants cared for after it was introduced (NeoMega period). The study has two parts: * European part: participating neonatal units report aggregated counts (number of infants and number with each outcome, by gestational week and period). No individual-level data leave the hospitals. * Swedish part: coded individual-level data are retrieved from the Swedish Neonatal Quality Register (SNQ) and the Swedish national register for ROP (SWEDROP). The study does not give, assign or change any treatment. NeoMega36 is given as part of routine clinical care according to each unit's own practice. There are no extra examinations, visits or contacts with families. The main hypothesis is that the proportion of infants with severe ROP is lower in the NeoMega period than in the historical period. Other outcomes are treated ROP, any ROP, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), death before discharge, and the combined outcomes BPD or death and NEC or death. Because this is a before-and-after comparison, differences between the periods may also reflect other changes in care over time, and the results will be interpreted with this in mind.

Gender: All

Ages: Any - 28 Days

Updated: 2026-11-18

Retinopathy of Prematurity (ROP)
Bronchopulmonary Dysplasia (BPD)
Necrotizing Enterocolitis (NEC)
+1
RECRUITING

NCT06333405

Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) - Clinical Study

The aim of the study is to assess the safety of fecal microbiota transplantation (FMT) as a preventive method for the development of Necrotizing enterocolitis (NEC) in a group of premature infants. This is the first stage of a clinical trial testing the effectiveness of FMT in NEC, the aim of which is to examine the safety profile and analyze all side effects.

Gender: All

Ages: 24 Weeks - 36 Weeks

Updated: 2026-11-05

1 state

Necrotizing Enterocolitis (NEC)
Necrotizing Enterocolitis of Newborn
RECRUITING

NCT07045844

Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants

The goal of this clinical trial is to evaluate whether supplementing with pasteurized donor human milk (pHDM) or preterm formula (PTF) when own mother's milk (OMM) is insufficient can improve outcomes in very preterm infants born before 29 weeks of gestation. It also aims to assess whether routine use of human milk fortifiers benefits this population. The main questions it aims to answer are: Does supplementing OMM with pHDM or PTF improve survival without surgery-requiring necrotizing enterocolitis (NEC) by 34 weeks corrected gestational age? Is routine fortification of human milk better than selective fortification based on growth faltering? Researchers will compare: pHDM vs. PTF to see which better supports survival without severe NEC. Routine fortification vs. selective fortification to assess the impact on growth and long-term neurodevelopment. Participants will: Be randomized twice: * First, within the first week of life to receive either pHDM or PTF when OMM is insufficient * Second, in the second week of life to receive either routine fortification or selective fortification only if growth faltering occurs Receive feeding and care as per standard clinical practice Complete neurodevelopmental assessment at 2 years corrected age using the Griffiths Mental Development Scales. This multicenter, double-randomized, open-label randomized controlled trial is embedded in routine neonatal care and uses real-world data to assess both short- and long-term outcomes. COLLABORATE-China is being run in partnership with the UK-wide COLLABORATE trial sponsored by Imperial College London.

Gender: All

Ages: 1 Day - 90 Days

Updated: 2026-10-26

10 states

Very Preterm Infant
Necrotizing Enterocolitis (NEC)
COMPLETED

NCT07765329

Higher-Dose Dexamethasone Improves Breathing and Shortens NICU Stay in Preterm Babies

The goal of this observational study was to compare two doses of dexamethasone given to pregnant women at risk of preterm birth. Dexamethasone is a medicine used before birth to help a baby's lungs mature. This study looked at preterm babies born between 26 and 36 weeks of pregnancy. Researchers compared babies whose mothers received dexamethasone 12 mg every 12 hours for 48 hours with babies whose mothers received dexamethasone 6 mg every 12 hours for 48 hours. The main questions this study aimed to answer were: * Did the higher dose of dexamethasone help preterm babies need breathing support for a shorter time? * Did the higher dose help shorten the babies' stay in the Neonatal Intensive Care Unit (NICU)? * Was the higher dose as safe as the lower dose for babies and mothers? Researchers reviewed medical records from Stella Maris Women's and Children's Hospital from January 2018 to January 2023. They looked at neonatal outcomes, including breathing support, respiratory distress syndrome, length of NICU stay, low blood sugar in babies, infection in mothers, and developmental problems at 24 months.

Gender: All

Ages: 26 Weeks - 36 Weeks

Updated: 2026-08-14

1 state

Premature Birth
Neonatal Hypoglycemia
Maternal Infection During Pregnancy
+7
RECRUITING

NCT06727877

Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach Based on Early Analysis of the Fecal Microbiota

Prematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neurodevelopmental morbidity. Its onset is unpredictable and sudden, usually between 10 and 20 days of life, and requires immediate, aggressive management: hemodynamic support, fasting, systemic antibiotic therapy or even surgery. Prevention is therefore essential, but systematic measures with proven efficacy (breastfeeding, early enteral feeding, multiple probiotics) are few and far between. What's more, these preventive measures cannot be modulated and adapted individually, since it is not possible to finely predict the risk of developing enterocolitis. Thus, the use of a predictive diagnostic test for NEC would make it possible to identify high-risk premature babies and develop personalized preventive measures. Changes in the digestive microbiota precede the onset of NEC, but it has not been possible to identify a reproducible and reliable microbial signature. As a result, the limited power of microbiota analysis and interpretation means that it cannot be used in practice to predict ECUN. Our partner team (MEDiS) has developed a bioinformatics chain (RiboTaxa) to obtain the precise structure of complex microbial communities from direct metagenomic sequencing data. Stool samples from international cohorts (1562 samples, 208 preterm infants) were then mined to train a deep neural network and generate a predictive diagnostic test for NEC. In a local study (10 cases and 10 controls), the predictive diagnostic performance of this test was 90%, with the 1ère stool identified as "at risk" preceding NEC by 8 days (extremes 4 - 17 days), and the 2nde by 2 days (extremes 0-7 days). We would now like to test our predictive diagnostic technique on a larger number of premature babies in the AURA region. 1000 children included, 200 children tested (50 NEC - 150 controls)

Gender: All

Ages: Any - 1 Day

Updated: 2026-04-06

Necrotizing Enterocolitis (NEC)
Healthy Control
RECRUITING

NCT00747851

NETs: Protection or Harm in Neonatal Inflammation or Infection

This is a prospective in vitro cell biology study of polymorphonuclear leukocyte (PMN) protein synthesis in response to PAF. PMNs from cord blood of premature human infants at risk for NEC (birth weight between 501 - 1500 grams) and PMNs from cord blood of healthy term infants will be isolated and stimulated with PAF, a biologically active phospholipid implicated in the pathogenesis of NEC. NEC, a disease of prematurity with an incidence of 10.1% of infants born weighing between 501 - 1500 grams, is associated with significant morbidity and mortality. We will compare the protein synthesis of inflammatory modulators, including Interleukin 6 Receptor alpha (IL-6R alpha) and Retinoic Acid Receptor alpha (RAR alpha) proteins to protein synthesis responses already observed in PMNs isolated from healthy adults. Furthermore, we will characterize the expression and activity of the mammalian target of rapamycin (mTOR) translational protein synthesis control pathway in PMNs isolated from preterm and term infants and compare those results with previous observations in PMNs isolated from adults. This pathway is known to regulate IL-6R alpha and RAR alpha protein expression in PMNs isolated from adults. We will also follow those premature infants at risk for NEC clinically to determine which infants develop NEC and what risk factors may be associated with NEC in this population.

Gender: All

Ages: Any - 1 Hour

Updated: 2025-12-05

1 state

Necrotizing Enterocolitis (NEC)
NOT YET RECRUITING

NCT06810154

Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants

The goal of this clinical trial is to evaluate whether multi-strain probiotics of lactobacillus and bifidobacterium can prevent necrotizing enterocolitis (NEC) in preterm infants born at less than 32 weeks of gestation. The main questions it aims to answer are: * Does the use of a multi-strain probiotic combination reduce the incidence of NEC in preterm infants? * Are there any adverse effects associated with the administration of this probiotic combination?

Gender: All

Ages: 0 Hours - 72 Hours

Updated: 2025-02-05

2 states

Necrotizing Enterocolitis (NEC)